About Professor Kazuaki Negishi

Prof Negishi is Professor of Medicine, Head of Discipline of Medicine at Sydney Medical School Nepean at the University of Sydney, Australia and adjunct Professor at Menzies Institute for Medical Research at University of Tasmania. He is also a Cardiologist at Nepean Hospital, NSW. Professor Negishi’s main areas of interest are 1) clinical application of invasive and non-invasive cardiovascular imaging; 2) environmental medicine, especially air pollution and cardiovascular disease; 3) tele-medicine; and 4) Cardio-Oncology. He had his Cardiology training and PhD in Japan, then spent three years in Cleveland Clinic, OH, USA before he came to Australia. He holds Fellowship recognitions from multiple international cardiac societies (FACC, FESC, FAHA, FASE, and FCSANZ). He is a Heart Foundation Future Leader Fellow of Australia (2018-2022).

Professor Negishi’s original research papers have been used to inform international guidelines and recommendation statements: “2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines” (Eur Heart J 2016;37:2768-2801) as well as “Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy” by American Society of Echocardiography and the European Association of Cardiovascular Imaging (Plana J Am Soc Echocardiogr 2014) cited two of his work (Negishi et al. J Am Soc Echocardiogr 2013 and EHJ cardiovasc Img 2014) as evidence-base for the cut-off value in their algorithm. In addition, consensus document from American Society of Echocardiography and the European Association of Cardiovascular Imaging on “definitions for 2D Speckle Tracking Echocardiography (Voigt J Am Soc Echocardiogr 2015) cited his work (Negishi Ultrasound Med Biol) as well.

Professor Negishi and his group are currently investing on 1) early/subclinical stages (A or B) heart failure, including diabetic cardiomyopathy and Cardio-Oncology. The primary modalities used for this are echocardiography (including myocardial strain analysis) and MRI (including T1 mapping). Echocardiography is the frontline tool in cardiology and provides essential information on clinical management. Myocardial strain analysis is a great example of recent advance in echocardiography, which allows early detection of subtle damage in myocardial in various type of cardiovascular diseases. 2) Prof Negishi's group has reinforced the association between air pollution (PM2.5) and out-of-hospital cardiac arrest (OHCA) among ~250,000 OHCA data in a lower level of air pollution. He also identified the lowest threshold of PM2.5 for the increase in heart failure incidence. 3) He is also working on a collaborative project with an engineering team at the University of Sydney, focusing on application of AI and ML on cardiovascular imaging and tele-health.

<html />

Selected publications